Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

Documenti analoghi

• Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
  di: Iro, M, et al.
  Pubblicazione: (2017)
• Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
  di: Iro, M, et al.
  Pubblicazione: (2016)
• Four component meningococcal capsular Group B vaccine in preterm infants.
  di: Sadarangani, M, et al.
  Pubblicazione: (2017)
• Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
  di: Pace, D, et al.
  Pubblicazione: (2016)
• Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
  di: Gossger, N, et al.
  Pubblicazione: (2012)